Send to a Friend Font Size: Increase Decrease

OrbiMed Advisors

OrbiMed Advisors's Portfolio

Last Updated on 5/16/11 @ 11:13am

Ticker	# of Shares	Price	Value
	73,114,592	$195.32	$14,280,742,110
	22,362,850	$195.32	$4,367,911,862
	17,233,668	$195.32	$3,366,080,034
	14,567,176	$195.32	$2,845,260,817
	9,033,726	$195.32	$1,764,467,363
	8,998,338	$195.32	$1,757,555,379
	8,322,140	$195.32	$1,625,480,385
	8,009,729	$195.32	$1,564,460,269
	7,619,135	$195.32	$1,488,169,449
View Additional Portfolio Information »

http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.

Login to help us fill in information about this entity.

View Older Stories View More Recent Stories

Jul 13, 2023 08:01PM Form 144 Galecto, Inc. Filed by: ORBIMED ADVISORS LLC
Jun 29, 2023 04:42PM Form 4 Passage BIO, Inc. For: Jun 27 Filed by: ORBIMED ADVISORS LLC
Jun 29, 2023 04:37PM Form SC 13D/A Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
Jun 29, 2023 04:30PM Form SC 13D/A Adicet Bio, Inc. Filed by: ORBIMED ADVISORS LLC
Jun 21, 2023 04:54PM Form SC 13D/A Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
Jun 15, 2023 04:35PM Form 144 Gracell Biotechnologies Filed by: ORBIMED ADVISORS LLC
Jun 13, 2023 01:57PM LSI USA Emerging Medtech Summit Returns to Dana Point March 18, 2024
May 24, 2023 04:57PM Form SC 13D VectivBio Holding AG Filed by: ORBIMED ADVISORS LLC
May 24, 2023 04:54PM Form SC 13D/A Prelude Therapeutics Filed by: ORBIMED ADVISORS LLC
May 17, 2023 04:47PM Form SC 13D/A SpringWorks Therapeutics Filed by: ORBIMED ADVISORS LLC
May 16, 2023 04:29PM Form SC 13D/A Fusion Pharmaceuticals Filed by: ORBIMED ADVISORS LLC
May 16, 2023 04:25PM Form SC 13D/A Verona Pharma plc Filed by: ORBIMED ADVISORS LLC
May 15, 2023 06:08PM Form 4 Verona Pharma plc For: May 11 Filed by: ORBIMED ADVISORS LLC
May 15, 2023 04:42PM Form 13F-HR ORBIMED ADVISORS LLC For: Mar 31
May 11, 2023 06:18PM Form 144 Verona Pharma plc Filed by: ORBIMED ADVISORS LLC
May 9, 2023 08:31AM Gilead Sciences (GILD) Announces Acquisition of XinThera
May 9, 2023 08:30AM Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
May 8, 2023 05:01PM Form SC 13D/A Kinnate Biopharma Inc. Filed by: ORBIMED ADVISORS LLC
May 5, 2023 11:15AM Form SC 13D/A Xtant Medical Holdings, Filed by: ORBIMED ADVISORS LLC
May 3, 2023 06:03AM Form SC 13D/A Kinnate Biopharma Inc. Filed by: ORBIMED ADVISORS LLC
May 2, 2023 09:35PM Form 4 Kinnate Biopharma Inc. For: Apr 28 Filed by: ORBIMED ADVISORS LLC
May 2, 2023 05:35PM Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 1, 2023 06:45AM W&T Offshore (WTI) Appoints Nancy Chang to its Board
May 1, 2023 06:45AM W&T Announces Addition to Its Board of Directors
May 1, 2023 06:00AM SINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-F
Apr 21, 2023 05:09PM Form 4 TELA Bio, Inc. For: Apr 19 Filed by: ORBIMED ADVISORS LLC
Apr 21, 2023 05:03PM Form SC 13D/A TELA Bio, Inc. Filed by: ORBIMED ADVISORS LLC
Apr 19, 2023 07:55PM Form 144 TELA Bio, Inc. Filed by: ORBIMED ADVISORS LLC
Apr 12, 2023 06:01AM Form SC 13D Apollomics Inc. Filed by: ORBIMED ADVISORS LLC
Apr 10, 2023 09:51PM Form 144 Galecto, Inc. Filed by: ORBIMED ADVISORS LLC
Apr 10, 2023 09:46PM Form 144 Galecto, Inc. Filed by: OrbiMed Advisors Israel II Ltd
Apr 10, 2023 09:43PM Form 144 Galecto, Inc. Filed by: ORBIMED ADVISORS LLC
Apr 7, 2023 04:39PM Form SC 13D/A Galecto, Inc. Filed by: ORBIMED ADVISORS LLC
Apr 5, 2023 05:29PM Form 144 Galecto, Inc. Filed by: OrbiMed Advisors Israel II Ltd
Apr 5, 2023 05:28PM Form 144 Galecto, Inc. Filed by: ORBIMED ADVISORS LLC
Apr 5, 2023 05:27PM Form 144 Galecto, Inc. Filed by: ORBIMED ADVISORS LLC
Mar 31, 2023 04:49PM Form SC 13D Gracell Biotechnologies Filed by: ORBIMED ADVISORS LLC
Mar 31, 2023 10:00AM Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
Mar 29, 2023 05:24PM Form SC 13D/A Terns Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Mar 27, 2023 07:00AM ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing
Mar 24, 2023 04:57PM Form SC 13D/A CalciMedica, Inc. Filed by: ORBIMED ADVISORS LLC
Mar 24, 2023 04:43PM Form SC 13D/A 89bio, Inc. Filed by: ORBIMED ADVISORS LLC
Mar 22, 2023 04:28PM Form SC 13D/A CalciMedica Inc Filed by: ORBIMED ADVISORS LLC
Mar 14, 2023 04:19PM Form SC 13D/A Theseus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Mar 6, 2023 08:00AM Congruence Therapeutics Announces Close of Series A Extension, Bringing Total Round to Over US$65 Million
Feb 28, 2023 05:31PM Form SC 13D/A Fusion Pharmaceuticals Filed by: ORBIMED ADVISORS LLC
Feb 28, 2023 04:00PM Form SC 13D Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC
Feb 27, 2023 08:31PM Form 4 Enliven Therapeutics, For: Feb 23 Filed by: ORBIMED ADVISORS LLC
Feb 23, 2023 03:23PM Form SC 13D/A Kinnate Biopharma Inc. Filed by: ORBIMED ADVISORS LLC
Feb 14, 2023 05:24PM Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: ORBIMED ADVISORS LLC

View More Recent Stories View Older Stories

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed